Prescription for Patience: Galaxy Medicare’s IPO Plays It Safe

Image Source: Finowings

As the IPO season continues to pulse through India’s SME exchange, Galaxy Medicare’s public offering has drawn moderate attention from investors, with a subdued grey market premium and a cautious subscription trend ahead of its listing on NSE EMERGE. The company, a seasoned player in the medical devices and surgical dressings space, opened its IPO from September 10 to 12, 2025, aiming to raise up to Rs 22.31 crore. While the fundamentals reflect a stable business model, the market’s response has been measured, signaling a wait-and-watch sentiment.

Key highlights
- IPO price band set between Rs 51 and Rs 54 per share
- Total issue size of 41.32 lakh shares, including fresh issue and offer for sale
- Retail quota at 35 percent, QIB at 50 percent, and NII at 15 percent
- Grey market premium (GMP) remained flat to mildly positive during the subscription window

1. Company Snapshot: A Legacy in Surgical Care
Galaxy Medicare has been operating for over three decades, manufacturing and exporting a wide range of medical products including Plaster of Paris bandages, surgical tapes, and orthopedic dressings.
- Holds 27 registered trademarks including POP BAND, G CAST, and CARETAPE
- Supplies to central and state health departments, corporate hospitals, and private players
- Export footprint includes Bangladesh, Nepal, and other South Asian markets
- FY 2024–25 revenue stood at Rs 39.20 crore, with net income of Rs 3.37 crore

2. IPO Structure and Allocation
The IPO comprises a fresh issue of 33.08 lakh shares and an offer for sale of 8.24 lakh shares. The minimum bid size was 4,000 shares, translating to an investment of Rs 2.16 lakh per retail investor.
- Retail investors offered 23.08 lakh shares, accounting for 55.86 percent of the issue
- Non-institutional investors (NII) allocated 15.36 lakh shares, split between small and big HNIs
- Qualified institutional buyers (QIBs) reserved 80,000 shares
- Market makers allotted 2.08 lakh shares to ensure liquidity

3. Subscription Trends: Lukewarm But Steady
Despite the company’s strong fundamentals, the IPO witnessed moderate subscription levels across categories.
- Retail portion saw steady but unspectacular interest
- NII segment showed higher traction among small HNIs
- QIB participation remained conservative, reflecting broader SME market caution
- Final subscription figures suggest a modest oversubscription, driven by retail and small HNI bids

4. Grey Market Signals: Flatline or Slow Uptick
The grey market premium for Galaxy Medicare hovered around Rs 5–7 during the subscription period, indicating limited speculative enthusiasm.
- GMP remained stable, with no sharp spikes or dips
- Kostak and subject-to-sauda rates were negligible, suggesting low retail flipping interest
- Analysts attribute the subdued GMP to cautious sentiment in the SME IPO space and valuation concerns

5. Financial Performance and Valuation
Galaxy Medicare’s financials show consistent growth, with improving margins and declining debt.
- EPS for FY 2025 at Rs 2.84, with a PE ratio between 17.96 and 19.01
- Return on net worth (RONW) at 18.35 percent, and ROCE at 23.38 percent
- Debt-to-equity ratio reduced to 0.25, reflecting prudent capital management
- EBITDA margin at 11.69 percent, indicating operational efficiency

6. Listing Outlook: Stability Over Speculation
With listing expected in late September 2025, market watchers anticipate a stable debut rather than a blockbuster opening.
- Conservative GMP suggests listing near issue price
- Long-term investors may find value in the company’s export-driven model and healthcare sector positioning
- Short-term gains likely to be limited unless broader SME sentiment improves

Closing thought
Galaxy Medicare’s IPO may not have set the market ablaze, but it offers a steady proposition in a sector that thrives on resilience and necessity. As India’s healthcare infrastructure expands and demand for quality medical supplies grows, Galaxy’s fundamentals could prove more valuable than its initial market buzz. For investors seeking substance over speculation, this IPO might just be worth a second diagnosis.

Sources: Chittorgarh, IPO Central, IPO Watch India